[{"data":1,"prerenderedAt":33},["ShallowReactive",2],{"project-41d75f4069ef5fe500d7ee1c324c3feb":3},{"_id":4,"slug":4,"title":5,"subtitle":6,"cover":8,"tech_type":9,"indications":10,"official_price":11,"hospital_name":12,"hospital_names":13,"landing_hospitals":14,"tech_company_name":21,"view_count":22,"favorite_count":23,"is_favorite":24,"approval_no":25,"approval_date":9,"regulatory_level":26,"valid_until":9,"filing_date":27,"intro":28,"detail_desc":29,"target_population":30,"compliance_list":31,"process":32},"41d75f4069ef5fe500d7ee1c324c3feb","预防肝癌术后复发的活化 T 淋巴细胞应用技术",[7],"肝癌","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/covers/cover-02.jpg","",[7],"10万/次","树兰(博鳌)医院",[12],[15],{"id":16,"name":12,"level":17,"city":18,"province":19,"dept":20},"f4fad4e069ef5fbe00da13601871b37a","三甲","琼海市","海南","肝胆外科 / 肿瘤中心","北京永泰生物制品有限公司",164,1,false,"乐城第四批获批","低风险","2025年","\u003Cp>自体活化 T 淋巴细胞回输,辅助根治性肝癌术后患者降低复发风险。\u003C/p>\u003Cp>\u003Cb>适应症\u003C/b>:肝癌术后辅助 / 预防复发\u003Cbr/>\u003Cb>技术类型\u003C/b>:前沿医疗\u003Cbr/>\u003Cb>批次\u003C/b>:乐城第四批获批\u003C/p>","自体活化 T 淋巴细胞回输,辅助根治性肝癌术后患者降低复发风险。",[],[],[],1780973403236]